The Brief

When PharmaJet’s innovative needle-free injection technology received FDA approval in 2014, the company tapped MAPR to develop a comprehensive communications plan in order to generate interest in PharmaJet’s technology, bolster credibility with retailers and pharmacists and begin to establish the PharmaJet brand as the predominant needle-free technology on the market.

The Work

To support PharmaJet’s launch and the significant growth potential for the company’s needle-free technology, the public relations program initially focused on influencing pharmacists, retail pharmacies and other healthcare professionals through the use of traditional public relations tactics as well as social media, infographics and blogging. Following a successful launch, the program continued to focus on content creation by way of eye-catching and informative infographics, contributed and other thought leadership opportunities, drafting and distributing press releases. The program also began developing an engaged social media audience, updating the PharmaJet website and utilizing SEO tactics to ensure users find PharmaJet online. 

The Results

In just the first year of our engagement, PharmaJet was able to grow both its Facebook community and its LinkedIn community as well as increasing the number of likes on the company’s YouTube channel. In addition, our SEO strategy in year one helped PharmaJet attract 130.8 percent more unique visitors and helped the company’s pages begin to climb in the search engine results pages (SERPs). With MAPR’s help, PharmaJet has secured coverage in pharmacy and healthcare outlets as well as national and local publications, including Digital JournalEveryday Health, Popular Science, Colorado Public Radio, Smithsonian and Washington Post.

Local politicians have found value in PharmaJet’s innovative technology, as well with CBS’ Denver affiliate station covering a story about Colorado’s governor, John Hickenlooper, receiving a needle-free flu shot from PharmaJet in 2014 and Colorado U.S. Senator Michael Bennet visiting PharmaJet’s headquarters in 2016 to highlight the need for emergency research funding to combat Zika virus.

Coverage